| Online-Ressource |
Verfasst von: | Diener, Hans-Christoph [VerfasserIn]  |
| Ringelstein, Erich Bernd [VerfasserIn]  |
| Kummer, Rüdiger von [VerfasserIn]  |
| Langohr, Hans Dieter [VerfasserIn]  |
| Bewermeyer, Heiko [VerfasserIn]  |
| Landgraf, Helmut [VerfasserIn]  |
| Hennerici, Michael G. [VerfasserIn]  |
| Welzel, Dieter [VerfasserIn]  |
| Gräve, Michael [VerfasserIn]  |
| Brom, Joachim [VerfasserIn]  |
| Weidinger, Gottfried [VerfasserIn]  |
Titel: | Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin |
Titelzusatz: | results of the TOPAS trial |
Verf.angabe: | Hans Christoph Diener, Erich Bernd Ringelstein, Rüdiger von Kummer, Hans Dieter Langohr, Heiko Bewermeyer, Helmut Landgraf, Michael Hennerici, Dieter Welzel, Michael Gräve, Joachim Brom, and Gottfried Weidinger |
E-Jahr: | 2001 |
Jahr: | [January 2001] |
Umfang: | 8 S. |
Fussnoten: | Gesehen am 31.03.2021 |
Titel Quelle: | Enthalten in: Stroke |
Ort Quelle: | New York, NY : Association, 1970 |
Jahr Quelle: | 2001 |
Band/Heft Quelle: | 32(2001), 1 vom: Jan., Seite 22-29 |
ISSN Quelle: | 1524-4628 |
Abstract: | Background and Purpose—To study the safety and efficacy of the low-molecular-weight heparin certoparin, we performed a randomized, double-blind, dose-finding multicenter trial in patients with acute ischemic stroke (Therapy of Patients With Acute Stroke [TOPAS]).Methods—We randomized 404 patients to 4 treatment groups within 12 hours of stroke onset: 3000 U anti-factor Xa (aXa) certoparin once daily (treatment group 1); 3000 U aXa twice daily (group 2); 5000 U aXa twice daily (group 3); and 8000 U aXa twice daily (group 4). The primary efficacy variable was the proportion of patients reaching a favorable functional outcome (Barthel Index ≥90 points) at 3 months. CT was performed at trial entry, after 7 days, and on clinical deterioration.Results—The proportion of patients with Barthel Index ≥90 was not different between treatment arms (61.5%, 60.8%, 63.3%, and 56.3% in the 4 groups, respectively; intent-to-treat population). European Stroke Scale scores improved in all treatment groups within the first 14 days to a similar extent. During the follow-up of 6 months, percentages of patients with recurrent stroke/transient ischemic attack were 11.0%, 5.9%, 9.7%, and 13.0% in the 4 groups, respectively. Overall mortality was only 7.4%. Two parenchymal cerebral hematomas and 1 extracranial bleeding episode occurred in treatment group 1 versus 1 and 0 in group 2, 2 and 0 in group 3, and 4 and 5 in group 4, respectively. During certoparin treatment, 1 deep vein thrombosis but no pulmonary embolism was observed.Conclusions—Dose increase of certoparin up to 8000 U aXa twice daily did not improve the functional outcome of patients with ischemic stroke. Severe bleeding tended to be more frequent in the highest dose group only. |
DOI: | doi:10.1161/01.STR.32.1.22 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1161/01.STR.32.1.22 |
| Volltext: https://www.ahajournals.org/doi/10.1161/01.str.32.1.22 |
| DOI: https://doi.org/10.1161/01.STR.32.1.22 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1752962990 |
Verknüpfungen: | → Zeitschrift |
Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin / Diener, Hans-Christoph [VerfasserIn]; [January 2001] (Online-Ressource)